EU Awards 2,6 Million Euros for Patients with Chronic Cardiorenal Disease

To help patients manage their (potential) chronic heart and kidney disease, the European Commission has awarded 2,6 million euros to the CARRE project. A group of interdisciplinary researchers will compile personalised alerting, planning and educational services. This will empower patients, and both professionals and patients will be able to make shared informed decisions on the disease.

Cardiorenal syndrome is the condition characterised by simultaneous kidney and heart failure while the primarily failing organ may be either the heart or the kidney. Very often the dysfunction occurs when the failing organ precipitates the failure of the other.

Current studies estimate that 9-16% of the overall population is at risk or at the onset of chronic kidney disease, while chronic heart failure amounts to 1-2% of total healthcare costs and end-stage renal disease for more than 2% of total healthcare.

Challenging
Managing or even preventing this complex but common situation can be challenging: Comorbidities require care provision by different medical specialities while addressing a chronic patient trying to lead a normal life.

According to Robert Johnstone of the International Alliance of Patient Organizations there is a clear need for "patients to get up off their knees"!

Interlinked clinical information
To tackle this problem, the European Commission has decided to fund the CARRE project. This project will use internet aware sensors and other sources of medical information to provide dynamically interlinked clinical information personalized to the patient.

Patients and clinicians will be able to visualise, understand and interact with this linked knowledge via a set of decision support service in an all-inclusive and integrated approach the patient with (or at risk of) cardiorenal disease and comorbidities.

Partners
The CARRE consortium consists of 6 partners from 4 countries (Greece, United Kingdom, Lithuania and Poland) and is coordinated by the Democritus University of Thrace in Alexandroupoli, Greece.

The project is driven by two partners from the medical domain, namely the Democritus University of Thrace and the Vilnius University Hospital Santariškių Klinikos (LT), with a clear long experience in medical research in cardiorenal disease and comorbidities as well as with a long record of developing and deploying successful informatics interventions in the real healthcare setting.

The core semantic model and interlinking is performed by The Open University (UK) a leading expert in semantic technologies, while the University of Bedfordshire (UK) undertakes the work on visual analytics and cloud computing - both partners also contribute their long experience in semantic information extraction from unstructured data sources and web service oriented architectures.

Personal sensors
Kaunas University of Technology (LT), with a long proven innovation experience in personal sensors and sensor networks for cardiorenal disease tackles the integration of personalized sensor data. Finally, the Industrial Research Institute for Automation and Measurements (PL), an established partner in security and automation systems, brings in the required expertise on decision support systems and on systems security and data privacy.

The overall aim of the CARRE project is to show the potential of semantic interlinking of heterogeneous data to construct dynamic personalized models of complex comorbid medical conditions with disease progression pathways and comorbidity trajectories. Also, to show that visual analytics based on such models can support patient understanding of personal complex conditions (projected against ground knowledge and statistical views of similar patient population) and be the basis for shared decision support services for the management of comorbidities.

Freely available
All CARRE outcomes will be available as open source, protected under Creative Commons or GNU-GPL and other similar appropriate licensing schemes. CARRE project outcomes will thus be freely available for use and re-use by any interested party. Proof-of-concept will be shown via deployment and evaluation in two different healthcare settings.

The CARRE project is expected to reinforce the cardiorenal patients' understanding of the disease and the complex interdependencies of existing or projected comorbidities, supporting personalized treatment stratification, monitoring alerts, education and shared informed decision making.

Through these outcomes, CARRE strengthens the EU resolution to put the chronic patient at the center.

For further information, please visit:
http://www.carre-project.eu

About CARRE project
The CARRE project investigates information and communication technologies for empowering patients with comorbidities (multiple co-occurring medical conditions), or persons with increased risk of such conditions, especially in the case of chronic cardiac and renal disease patients. The CARRE project has received a 3-year EC funding from the European Community 7th Framework Programme FP7-ICT-2013 work programme under grant agreement no. 611140.

Most Popular Now

Significant Disparities in Telemedicine …

After "COVID-19," the term that most people will remember best from 2020 is likely to be "social distancing." While it most commonly applied to social gatherings with family and friends...

Model Used to Evaluate Lockdowns was Fla…

In a recent study, researchers from Imperial College London developed a model to assess the effect of different measures used to curb the spread of the coronavirus. However, the model...

Using Artificial Intelligence to Find Ne…

Scientists have developed a machine-learning method that crunches massive amounts of data to help determine which existing medications could improve outcomes in diseases for which they are not prescribed. The intent...

FDA Releases Artificial Intelligence / M…

Today, the U.S. Food and Drug Administration released the agency's first Artificial Intelligence/Machine Learning (AI/ML)-Based Software as a Medical Device (SaMD) Action Plan. This action plan describes a multi-pronged approach...

New Virtual Screening Strategy Identifie…

A novel computational drug screening strategy combined with lab experiments suggest that pralatrexate, a chemotherapy medication originally developed to treat lymphoma, could potentially be repurposed to treat COVID-19. Haiping Zhang...

CliniSys Launches Laboratory Information…

CliniSys has launched a new laboratory information management system for genomic laboratories in the UK. The company has brought GLIMS Genomics to the UK from Europe, where it is being...

The Institute of Healthcare Management C…

The Institute of Healthcare Management has called for honest and open communication about NHS capacity after a snapshot survey revealed the scale of sickness absence across the service. The UK's leading...

One in Four Doctors Attacked, Harassed o…

While many physicians benefit from social media by networking with potential collaborators or interfacing with patients, a new study from Northwestern University and the University of Chicago found many physicians...

First NHS Trust and Sectra Achieve Rapid…

A new region-wide approach to analysing x-rays, MRI scans, CT scans, mammography, and an entire range of crucial diagnostic images, has started to become reality, now that The Pennine Acute...

Abbott to Launch the NeuroSphere™ myPath…

Abbott (NYSE: ABT) today announced the upcoming launch of NeuroSphere™ myPath™, a digital health app designed to track and report on patient perceived pain relief and general well-being associated with...

Bayer Transforms Pharma Business through…

At its virtual Pharma Media Day, Bayer presented exciting progress in transforming its pharmaceutical business with breakthrough innovation in healthcare that will significantly help patients suffering from conditions that are...